Fusion Antibodies Plc (GB:FAB) has released an update.
Fusion Antibodies Plc, a specialist in pre-clinary antibody discovery and engineering, has announced that its Non-Executive Chair, Simon Douglas, has invested in the company by purchasing 150,000 ordinary shares. This acquisition increases Douglas’s direct holding to approximately 0.86% of the company’s issued share capital. The transaction, conducted on the London Stock Exchange, reflects a vote of confidence in the company’s growth strategy and services in the pharmaceutical and diagnostic sectors.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.
